- Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
- Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
- Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
- Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
- Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
- Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
More ▼
Key statistics
On Friday, Minerva Neurosciences Inc (NERV:NAQ) closed at 3.22, 42.48% above the 52 week low of 2.26 set on May 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.26 |
---|---|
High | 3.47 |
Low | 3.02 |
Bid | 3.22 |
Offer | 3.40 |
Previous close | 3.36 |
Average volume | 115.97k |
---|---|
Shares outstanding | 6.99m |
Free float | 5.44m |
P/E (TTM) | -- |
Market cap | 20.21m USD |
EPS (TTM) | -4.48 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼